Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLL

Clinical trial NCT04908228 · RECRUITING

Trial details

NCT number: NCT04908228
Sponsor: Paolo Ghia
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia

Start date: 2021-12-13
Primary completion: 2026-09-15
Enrollment: 53

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.